Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
RATIONALE: Many studies have reported deficits of mismatch negativity (MMN) in schizophrenic patients. Pharmacological challenges with hallucinogens in healthy humans are used as models for psychotic states. Previous studies reported a significant reduction of MMN after ketamine (N-methyl-D-aspartate acid [NMDA] antagonist model) but not after psilocybin (5HT2A agonist model). OBJECTIVES: The aim of the present study was to directly compare the two models of psychosis using an intraindividual crossover design. MATERIALS AND METHODS: Fifteen healthy subjects participated in a randomized, double-blind, crossover study with a low and a high dose of the 5HT2A agonist dimethyltryptamine (DMT) and the NMDA antagonist S-ketamine. During electroencephalographic recording, the subjects were performing the AX-version of a continuous performance test (AX-CPT). A source analysis of MMN was performed on the basis of a four-source model of MMN generation. RESULTS: Nine subjects completed both experimental days with the two doses of both drugs. Overall, we found blunted MMN and performance deficits in the AX-CPT after both drugs. However, the reduction in MMN activity was overall more pronounced after S-ketamine intake, and only S-ketamine had a significant impact on the frontal source of MMN. CONCLUSIONS: The NDMA antagonist model and the 5HT2A agonist model of psychosis display distinct neurocognitive profiles. These findings are in line with the view of the two classes of hallucinogens modeling different aspects of psychosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mismatch negativity (MMN) in basic research of central auditory processing: A review
Näätänen, R., Paavilainen, P., Rinne, T., & Alho, K. (2007) · Clinical Neurophysiology · doi:10.1016/j.clinph.2007.04.026 · Cited by 2,644 · cited 1×
“Nevertheless, even though several studies support a frontal lobe involvement in MMN generation (for a review, see Näätänen et al. 2007), we cannot exclude that the frontal source is simply an artifact due to the inverse problem of source analyses.”
BackgroundPsilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 1×
“LSD-type drugs are agonists at serotonin 5HT2A receptors, and the 5HT2A agonist model of psychosis is thought to resemble more the positive symptoms of schizophrenia (Abi-Saab et al. 1998; Gouzoulis-Mayfrank et al. 2005; Vollenweider et al. 1998).”
BackgroundMismatch negativity in schizophrenia: a meta-analysis
Umbricht, D., & Krljes, S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.12.002 · Cited by 742
Javitt, D. C., Steinschneider, M., Schroeder, C. E., & Arezzo, J. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11962 · Cited by 662
Mismatch Negativity Deficits Are Associated With Poor Functioning in Schizophrenia Patients
Light, G. A., & Braff, D. L. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.127 · Cited by 407 · cited 2×
“It is noteworthy that recent studies reported an association between MMN deficits and poor functioning in schizophrenia (Light and Braff 2005a, b).”
BackgroundTodd, J., Michie, P. T., Schall, U., Karayanidis, F., Yabe, H., & Näätänen, R. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.02.016 · Cited by 257
The NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls
Abi-Saab, W., D'Souza, D., Moghaddam, B., & Krystal, J. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979354 · Cited by 208
Kreitschmann-Andermahr, I., Rosburg, T., Meier, T., Volz, H.-P., Nowak, H., & Sauer, H. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00115-7 · Cited by 87
Cited by
The mismatch negativity: a review of underlying mechanisms
Garrido, M. I., Kilner, J. M., Stephan, K. E., & Friston, K. J. (2009) · Clinical Neurophysiology · doi:10.1016/j.clinph.2008.11.029 · Cited by 1,441
“…through NMDA receptors: several studies have found strong reductions of MMN amplitude under the NMDA antagonist ketamine (Ehrlichman et al., 2008; Heekeren et al., 2008; Javitt et al., 1996; Kreitschmann-Andermahr et al., 2001; Umbricht et al., 2000, 2002), with only a single study failing to…”
BackgroundMoghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532
Näätänen, R., Kujala, T., Escera, C., Baldeweg, T., Kreegipuu, K., Carlson, S., & Ponton, C. (2012) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.09.020 · Cited by 425
Auditory dysfunction in schizophrenia: integrating clinical and basic features
Javitt, D. C., & Sweet, R. A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4002 · Cited by 367
Metadata
- Authors
- Heekeren, K., Daumann, J., Neukirch, A., Stock, C., Kawohl, W., Norra, C., Waberski, T. D., & Gouzoulis-Mayfrank, E.
- Venue
- Psychopharmacology
- Published
- 2008-05-18
- Volume
- 199
- Issue
- 1
- Pages
- 77-88
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2037891934
- Cited by
- 152
- References
- 8
- FWCI
- 11.49
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.